BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Penn Engineering Events - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Penn Engineering Events
X-ORIGINAL-URL:https://seasevents.nmsdev7.com
X-WR-CALDESC:Events for Penn Engineering Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240124T153000
DTEND;TZID=America/New_York:20240124T163000
DTSTAMP:20260403T211419
CREATED:20240116T174749Z
LAST-MODIFIED:20240116T174749Z
UID:10454-1706110200-1706113800@seasevents.nmsdev7.com
SUMMARY:CBE Seminar: "Bioinspired Protein-Based Cancer Immunotherapy" (Yanpu He\, MIT)
DESCRIPTION:Abstract:\nImmunotherapy has revolutionized the field of cancer treatment over the past two decades\, though only a small fraction of patients treated will achieve complete remission. As such\, new paradigms to overcome resistance to immunotherapies are urgently needed. My research seeks to tailor immunotherapies towards individual differences in immune systems and the inherent heterogeneity of cancer. For this talk\, I will share my work on a key therapeutic target against cancer called the STimulator of INterferon Genes (STING) signaling. I first addressed an innate immunodeficiency caused by a loss-of-function mutation of STING protein affecting 20% of the human population\, using the cytosolic domain of STING (STINGΔTM) as a functional agonist carrier to activate signaling in STING-deficient cells. Subsequently\, I developed a therapeutic cancer vaccine based on this platform by fusing STINGΔTM with immune checkpoint blockade (ICB) nanobodies. The treatment eliminated subcutaneous colon and melanoma tumors in 70-100% of mice and protected all cured mice against rechallenge\, while mechanistic studies revealed a distinct STING-mediated anti-tumor immunity driven by robust TH1 polarization and Treg suppression in CD4+ T cells\, followed by the collaboration of CD8+ T and NK cells to eliminate tumors. For my independent group\, I will continue these prospects in designing protein therapeutics and leveraging the full potential of CD4+ T cells\, initially towards personalized cancer immunotherapies and expanding to other monogenic immunodeficiencies and drug delivery challenges in the long run.
URL:https://seasevents.nmsdev7.com/event/cbe-seminar-bioinspired-protein-based-cancer-immunotherapy-yanpu-he-mit/
LOCATION:Wu and Chen Auditorium (Room 101)\, Levine Hall\, 3330 Walnut Street\, Philadelphia\, PA\, 19104\, United States
CATEGORIES:Seminar
ORGANIZER;CN="Chemical and Biomolecular Engineering":MAILTO:cbemail@seas.upenn.edu
END:VEVENT
END:VCALENDAR